Unknown

Dataset Information

0

Pharmacokinetic Study of NADPH Oxidase Inhibitor Ewha-18278, a Pyrazole Derivative.


ABSTRACT: In a previous study, the specific NOX1/2/4 inhibitor Ewha-18278 was confirmed as a possible treatment for osteoporosis both in vitro and in vivo. Here, we investigated the pharmacokinetics (PK) of the compound by intravenous (IV) and oral administrations to rats. Dimethyl sulfoxide (DMSO)-based and diazepam injection-based formulations were used to dissolve the compound. In the latter formulation applicable to humans, the changes in PK parameters were monitored at two different concentrations (1 mg/mL and 2 mg/mL). The area under the plasma concentration-time curve from zero time to infinity (AUCinf) of Ewha-18278 was highest in the DMSO-based formulation (2 mg/mL). Also, the concentration was increased 1.6-fold at the low concentration of the diazepam injection-based formulation compared to the high concentration. There was no statistical significance in the AUCinf of the compound between DMSO-based formulation (2 mg/mL) and diazepam injection-based formulation (1 mg/mL). These results suggest that Ewha-18278 can be delivered to humans by both IV and oral routes. In addition, the diazepam injection-based formulation of Ewha-18278 appears to be a suitable candidate for dosage development for future toxicity test and clinical trial.

SUBMITTER: Lee SG 

PROVIDER: S-EPMC6781499 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetic Study of NADPH Oxidase Inhibitor Ewha-18278, a Pyrazole Derivative.

Lee Seul Gee SG   Lee Jaeok J   Kim Kyung Min KM   Lee Kee-In KI   Bae Yun Soo YS   Lee Hwa Jeong HJ  

Pharmaceutics 20190917 9


In a previous study, the specific NOX1/2/4 inhibitor Ewha-18278 was confirmed as a possible treatment for osteoporosis both in vitro and in vivo. Here, we investigated the pharmacokinetics (PK) of the compound by intravenous (IV) and oral administrations to rats. Dimethyl sulfoxide (DMSO)-based and diazepam injection-based formulations were used to dissolve the compound. In the latter formulation applicable to humans, the changes in PK parameters were monitored at two different concentrations (1  ...[more]

Similar Datasets

| S-EPMC4792161 | biostudies-literature
| S-EPMC7654245 | biostudies-literature
| S-EPMC9951936 | biostudies-literature
| S-EPMC4545375 | biostudies-literature
| S-EPMC7701520 | biostudies-literature
| S-EPMC2634351 | biostudies-literature
| S-EPMC9079095 | biostudies-literature
2021-08-05 | GSE181476 | GEO
| S-EPMC3095934 | biostudies-literature
| S-EPMC6161897 | biostudies-literature